HIV Type 1 Subtypes Based on the <i>pol</i> Gene and Drug Resistance Mutations Among Antiretroviral-Naive Patients from Guangxi, Southern China

Su, Qi-jian; Liang, Hao; Cen, Ping; Bi, Zhi-you; Zhou, Ping

doi:10.1089/aid.2011.0246

Cited by 16 publications

(21 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This conclusion is placed in the WHO range that reports the prevalence of moderate drug resistance between 5 and 15% [9,21]. In the current study, no drug resistance mutations were assessed in the NNRTI class among naïve patients; there is a concordance between this result and 2 previous studies [10,22]. However, the result is inconsistent with other studies reporting NNRTI mutations in naïve patients [1,23].…”

Section: Discussioncontrasting

confidence: 44%

HIV Drug Resistance and Phylogeny Profile in Naïve and Antiretroviral-Experienced Patients in Tehran, Iran

Farrokhi

Moallemi²,

Baesi³

et al. 2016

Intervirology

View full text Add to dashboard Cite

Background: Increasing the accessibility of antiretroviral therapy (ART) has caused the emergence of drug resistance in patients receiving ART and in naïve patients. The aim of this study was to evaluate HIV subtype and drug resistance between naïve patients and ART-experienced patients. Methods: Blood samples were collected from 78 antiretroviral and naïve HIV-1 patients; antiretroviral-resistant mutations and subtyping were then determined by sequencing pol regions. Results: Phylogenetic analysis revealed that 96.1% of sequences belong to the CRF35-AD subtype. Transmitted drug resistance was determined in 14% of drug-naïve patients and 40% of ART-experienced patients. Conclusion: The findings of this study illustrated the importance of resistance testing before and during ART treatment. This study can be used to set up a best medicine strategy in Iranian guidelines.

show abstract

Section: Discussioncontrasting

confidence: 44%

HIV Drug Resistance and Phylogeny Profile in Naïve and Antiretroviral-Experienced Patients in Tehran, Iran

Farrokhi

Moallemi²,

Baesi³

et al. 2016

Intervirology

View full text Add to dashboard Cite

show abstract

“…Clearly, the number of individuals who had received free ART dramatically increased from since June 2010 under the 5 years anti-HIV programme run by the Guangxi Government, China. In 2008, Su et al [15] analysed 124 HIV-infected, ARV-naive patients enrolled from Liuzhou and Nanning, Guangxi. The results showed that the prevalence of transmitted HIV drug resistance was 1.6%.…”

Section: Discussionmentioning

confidence: 99%

“…Our study shows that the prevalence of TDR in Guangxi is 3.2%. Furthermore, Su et al [15] did not find TDR in NNRTI. Mutations of this type were seen our in study and that of Li et al [16] with a prevalence of 1.9 and 0.5%, respectively.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Prevalence of Transmitted HIV-1 Drug Resistance Remains Low in Guangxi, China, Eight Years after Scale-Up of Highly-Active Antiretroviral Therapy

Li¹,

Liang

Harrison

et al. 2014

Intervirology

View full text Add to dashboard Cite

Objectives: Highly-active antiretroviral therapy (HAART) was scaled up in Guangxi, China in 2005. The number of individuals receiving free HAART increased dramatically from June 2010 under the Guangxi Government's anti-HIV programme. We aimed to determine the prevalence of HIV-transmitted drug resistance (TDR) of Guangxi. Methods: HIV-positive, antiretroviral-naive individuals were recruited from the east (Hezhou), south (Qinzhou), west (Baise), north (Guilin) and centre (Laibin) of Guangxi. The pol gene of the virus from the individuals was analysed. Results: The overall prevalence of HIV TDR was 3.2% (7/216, 95% CI 0.9-5.5). The prevalence rates in Baise, Guilin, Hezhou, Qinzhou and Laibin are 4.9% (2/41, 95% CI -1.7 to 11.5), 2.3% (1/44, 95% CI -2.1 to 5.7), 4.7% (2/43, 95% CI -1.6 to 11.0), 2.6% (1/38, 95% CI -2.5 to 7.7) and 2.0% (1/50, 95% CI -1.9 to 5.9), respectively. No significant difference in the prevalence was found among them. No factors were found to be associated with TDR, including CD4 cell counts, viral loads and genotypes. The subtypes CRF01_AE, CRF07_BC, CRF08_BC and B were found. Subtype CRF08_BC is the predominant subtype in Baise while CRF01_AE is the predominant subtype elsewhere in Guangxi. Conclusions: The prevalence of TDR in antiretroviral-naive patients in Guangxi remains low 8 years after scale-up of HAART.

show abstract

“…CRF01_AE and CRF08_BC were two major subtypes in Guangxi. 6 Reports in recent years in Guangxi showed that CRF01_AE had dominated in the central city Nanning and the eastern city Liuzhou, 7 and there may be more than one introduction of CRF01_AE in Guangxi. 8 To gain a deeper understanding on the evolution of the HIV-1 epidemic and genetic characterization of CRF01_AE in Guangxi, we recruited 349 HIV/AIDS patients from cities all over Guangxi.…”

mentioning

confidence: 99%

Emergence of a New HIV Type 1 CRF01_AE Variant in Guangxi, Southern China

Zeng

Sun

Liang

et al. 2012

AIDS Research and Human Retroviruses

View full text Add to dashboard Cite

The distribution of HIV-1 subtypes and genetic characterization of CRF01_AE in Guangxi, southern China were identified. The distribution of HIV-1 genotypes based on gag, pol, and partial env sequences (n=349) was as follows: CRF01_AE (66.5%), CRF08_BC (19.2%), CRF07_BC (7.2%), URF (4.6%), subtype B (1.7%), and subtype B' (0.9%). CRF01_AE predominated in all geographic regions and risk populations and there were multiple introductions of CRF01_AE strains in Guangxi. We found a peculiar CRF01_AE monophyletic lineage distinct from other CRF01_AE viruses, and we designated it "CRF01_AE-v" for convenience. CRF01_AE-v circulating in both heterosexuals and injecting drug users (IDUs) had accounted for 39.7% of CRF01_AE. It showed a selective advantage in the Guangxi population and formed its own characteristic compared with all the CRF01_AE references. Our results suggested that CRF01_AE-v was a new variant of CRF01_AE and it might lead to a new epidemic in Guangxi.

show abstract

HIV Type 1 Subtypes Based on the pol Gene and Drug Resistance Mutations Among Antiretroviral-Naive Patients from Guangxi, Southern China

Cited by 16 publications

References 10 publications

HIV Drug Resistance and Phylogeny Profile in Naïve and Antiretroviral-Experienced Patients in Tehran, Iran

HIV Drug Resistance and Phylogeny Profile in Naïve and Antiretroviral-Experienced Patients in Tehran, Iran

Prevalence of Transmitted HIV-1 Drug Resistance Remains Low in Guangxi, China, Eight Years after Scale-Up of Highly-Active Antiretroviral Therapy

Emergence of a New HIV Type 1 CRF01_AE Variant in Guangxi, Southern China

Contact Info

Product

Resources

About